{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-048687","form_type":"8-K","ticker":"JUNS","cik":"0001679628","company_name":"JUPITER NEUROSCIENCES, INC.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.203130+00:00","generated_at":"2026-05-29T08:43:26.456953+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00","bullets":["IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.","Net proceeds to Jupiter are approximately $9.5M after underwriting discounts and expenses.","Shares began trading on Nasdaq Capital Market on Dec 3, 2024 under ticker JUNS.","Proceeds earmarked for Phase II trial of JOTROL in Parkinson's, SE Asia initiatives, R&D, license fees, debt repayment, and working capital.","Dominari Securities acted as lead underwriter; Revere Securities as co-manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-048687","json":"https://secwatch.observer/filing/0001493152-24-048687.json","markdown":"https://secwatch.observer/filing/0001493152-24-048687.md","text":"https://secwatch.observer/filing/0001493152-24-048687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679628/000149315224048687/0001493152-24-048687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679628/000149315224048687/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:43:26.456953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}